- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06060561
Genetic Testing to Improve Management of Patients Undergoing Breast Biopsy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. To collect saliva from 500 consenting women undergoing a clinically indicated breast biopsy, perform genotyping, and then assess the associations of polygenic risk score (PRS) (and related single nucleotide polymorphisms [SNPs]) to final diagnosis of ductal carcinoma in situ (DCIS), invasive breast cancer or benign breast disease (BBD); BBD severity; specific BBD lesions; and features of background benign lobules from which these lesions arise.
II. To relate PRS (and related SNPs) to radiologic features, including breast density and sentinel lesions, such as masses, densities, calcifications, and asymmetries.
III. To relate PRS (and related SNPs) to molecular markers in pathologic lesions and background tissues, including associations with breast cancer (BC) molecular subtypes (e.g., luminal, triple-negative (basal) and human epidermal growth factor receptor 2 [HER2] overexpressing) and biomarkers in BBD and lobules.
OUTLINE: This is an observational study.
Patients undergo saliva sample collection and complete questionnaires on study. Patients' medical records are reviewed.
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Locations
-
-
Florida
-
Jacksonville, Florida, United States, 32224-9980
- Recruiting
- Mayo Clinic in Florida
-
Principal Investigator:
- Mark E. Sherman, M.D.
-
Contact:
- Clinical Trials Referral Office
- Phone Number: 855-776-0015
- Email: mayocliniccancerstudies@mayo.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
* Women over the age of 18 years
- Able to provide informed consent
- Referred for a radiologically guided breast biopsy
Exclusion Criteria:
* Men
- Women under the age of 18 years
- Unable to provide informed consent
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Observational
Patients undergo saliva sample collection and complete questionnaires on study.
Patients' medical records are reviewed.
|
Non-interventional study
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of subjects consented per month
Time Frame: Baseline; Up to study completion (approximately 5 years)
|
Will be assessed by the percentage of eligible patients consented.
|
Baseline; Up to study completion (approximately 5 years)
|
Deoxyribonucleic acid (DNA) quantity
Time Frame: Up to study completion (approximately 5 years)
|
Will analyze DNA from saliva sample to assess quantity for a validated polygenic risk score (PRS) for breast cancer.
|
Up to study completion (approximately 5 years)
|
Deoxyribonucleic acid (DNA) quality
Time Frame: Up to study completion (approximately 5 years)
|
Will analyze DNA from saliva sample to assess quality for a validated PRS for breast cancer.
|
Up to study completion (approximately 5 years)
|
Ability to perform genotyping using collected sample
Time Frame: Up to study completion (approximately 5 years)
|
Will perform genotyping on collected saliva sample using the Infinium Global Diversity Array test to generate a validated polygenic risk score (PRS) for breast cancer.
Test results will be reviewed to assess whether the saliva sample contains enough (quantity) viable (quality) deoxyribonucleic acid (DNA) to provide accurate genotype results.
|
Up to study completion (approximately 5 years)
|
Success in estimation of polygenic risk score (PRS)
Time Frame: Up to study completion (approximately 5 years)
|
Medical records will be reviewed and compared with study findings to determine success of PRS estimation.
|
Up to study completion (approximately 5 years)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Mark E. Sherman, M.D., Mayo Clinic
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 22-011193 (Other Identifier: Mayo Clinic Institutional Review Board)
- NCI-2023-06044 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Carcinoma
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)CompletedInvasive Breast Carcinoma | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | Lobular Breast Carcinoma | Postmenopausal | Ductal Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
National Cancer Institute (NCI)Active, not recruitingBreast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast CarcinomaUnited States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)CompletedMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in SituUnited States
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingCancer Survivor | Invasive Breast Carcinoma | Ductal Breast Carcinoma In SituUnited States
-
Mayo ClinicNational Cancer Institute (NCI)Active, not recruitingEstrogen Receptor Positive | Ductal Breast Carcinoma In Situ | Grade 1 Invasive Breast Carcinoma | Grade 2 Invasive Breast Carcinoma | Grade 3 Invasive Breast Carcinoma | Invasive Ductal and Lobular Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast CarcinomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); Cianna Medical, Inc.TerminatedStage I Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIC Breast Cancer | Lobular Breast Carcinoma In Situ | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Ductal Breast Carcinoma In Situ | Mucinous Breast Carcinoma | Tubular Breast Carcinoma and other conditionsUnited States
-
Ohio State University Comprehensive Cancer CenterWithdrawnStage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Ductal Breast Carcinoma in Situ | Lobular Breast Carcinoma in Situ
-
University of Southern CaliforniaNational Cancer Institute (NCI); California Breast Cancer Research ProgramCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Ductal Breast Carcinoma in Situ | BRCA1 Mutation Carrier | BRCA2 Mutation Carrier | Lobular Breast Carcinoma in SituUnited States
-
Sunnybrook Health Sciences CentreActive, not recruitingBreast Cancer | Invasive Lobular Breast Carcinoma | Invasive Ductal Breast CarcinomaCanada
-
Case Comprehensive Cancer CenterWithdrawnStage I Breast Cancer | HER2-positive Breast Cancer | Male Breast Cancer | Stage II Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast Cancer | HER2-negative Breast... and other conditionsUnited States
Clinical Trials on Non-Interventional Study
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
University Hospital, RouenRecruitingDyspepsia | Irritable Bowel Syndrome | Functional Constipation | Faecal IncontinenceFrance
-
Mayo ClinicRecruitingOropharyngeal Squamous Cell Carcinoma | Recurrent Oropharyngeal Squamous Cell Carcinoma | Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Clinical Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 | Stage III Oropharyngeal (p16-Negative)... and other conditionsUnited States
-
Mayo ClinicNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute...RecruitingMalignant Solid Neoplasm | Hematopoietic and Lymphatic System NeoplasmUnited States
-
Mayo ClinicRecruitingStage 0a Bladder Cancer AJCC v8 | Stage 0is Bladder Cancer AJCC v8 | Stage I Bladder Cancer AJCC v8 | Stage IIIA Bladder Cancer AJCC v8 | Stage II Bladder Cancer AJCC v8United States
-
Mayo ClinicRecruitingClear Cell Renal Cell Carcinoma | Urothelial Carcinoma | Chromophobe Renal Cell Carcinoma | Papillary Renal Cell Carcinoma | Kidney Oncocytoma | Clear Cell Papillary Renal TumorUnited States
-
Mayo ClinicRecruitingProstate CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI); National Institute for Biomedical Imaging...RecruitingProstate NeoplasmUnited States
-
University of WashingtonNational Cancer Institute (NCI)RecruitingRecurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal CarcinomaUnited States
-
Mayo ClinicRecruitingBreast CarcinomaUnited States